The clinical trials industry has become one of the most complex and rapidly changing arenas in the healthcare market; the increasing complexity of studies, the rising awareness towards drug safety and an increasingly stringent regulatory environment have all contributed towards the rising costs and have been key in mandating the quest for a new approach.
Synexus has been recognised as leading the revolution of the clinical trials industry via its innovative, centralised model. The introduction of this system is the next step in that journey and will provide Synexus with unrivalled control of the entire study lifecycle.
Clinical trials budgets run into hundreds of millions of dollars. Therefore the importance of effective clinical trial management cannot be overestimated. Understanding and predicting the exact performance of a large phase III trial can be a daunting and challenging task. Systems previously available to the market follow the accrual method which has a number of limitations. Not least the lack of flexibility and forecasting enabling the entire enrolment picture to be modelled. The new system provides a consolidated view which facilitates communication across all stakeholders. Michael Fort, Chief Executive at Synexus said: “It is not uncommon for spreadsheets to be used for modelling and forecasting. Such systems lack enterprise class functionality and keeping multiple systems up-to-date and synchronised is error prone and an administrative nightmare.”
Combined with the administrative burden the increasingly complex environment is having a further impact on human resource costs due to the regulatory authorities’ need for more data. For an industry which is already struggling with increasing costs this is an unwelcome burden.
The IBM solution which has been developed in partnership with Synexus has a number of far reaching benefits. The best-in-class solution will further differentiate the Synexus’ model as an example of innovation which adds significant value. Amongst other benefits the solution will enable Synexus to know whether it is forecasting sufficient patient numbers to meet study goals, whether patient are being enrolled fast enough to meet end points, which Centres are underperforming, whether there is adequate balance between cost and performance and how much it will cost to get enrolment back on target.
In partnership with Enterprise BI, Synexus is also implementing an IBM Cognos 8 Planning solution which will allow modelling and tracking of clinical budgets and contract proposals. This provides powerful based forecasting and ‘what if’ scenario modelling which is far more beneficial when compared to rigid budgeting processes.
About Synexus
www.synexus.com
Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment and running of late stage clinical trials by full time GCP trained investigators at its own clinical trial sites.
Synexus® recruits participants for clinical trials on behalf of pharmaceutical, biotech and CROs. The clinical trials are then run and managed by Synexus® at 16 sites across the UK, Poland, Hungary, Bulgaria, India and South Africa.
Synexus® currently has more than ten thousand patients enrolled in clinical trials.
